A Phase 2/3 interventional study of infigratinib 0.128 mg/kg/day and infigratinib 0.25 mg/kg/day in Hypochondroplasia, sponsored by QED Therapeutics, a BridgeBio company. Enrolling by invitation at 24 sites in 10 countries. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-07-16.
Sponsored by QED Therapeutics, a BridgeBio company (part of BridgeBio) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Mucopolysaccharidosis IV with a site in United States — 16 open to participants now, 18 under way, 1 of them phase 3. Mucopolysaccharidosis IV · United States.
Among the 56 studies in Mucopolysaccharidosis IV with a site in United States, this one is the 23rd largest by planned enrollment of the 30 interventional ones that give a count, is one of 6 that started in 2025, is the only one in phase 2/3, reaches primary completion later than 4 of the 17 other live ones, and was the 48th registered.
101 studies on the registry are indexed under Mucopolysaccharidosis IV; 27 are open to participants now.
Browse Mucopolysaccharidosis IV studies →16 of the 56 studies in Mucopolysaccharidosis IV with a site in United States are open now. Recruiting first, the newest first:
Kiwi Health Inc · Sites in United States
Ages 18+ · Healthy volunteers
QED Therapeutics, a BridgeBio company · Sites in United States, Australia, Canada and 4 more countries
Ages 0 yrs–32 mo
Children's Hospital of Orange County · Sites in United States
Ages 0–99 · Healthy volunteers
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Sites in United States
Ages 2–100
QED Therapeutics, a BridgeBio company · Sites in United States, Australia, Canada and 7 more countries
Ages 30 mo–16 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 20 Mucopolysaccharidosis IV studies recruiting now, 9 (45%) set no upper age limit and 7 (35%) stop at 75 or younger; 15 take children under 18; 7 take healthy volunteers.
This study: 3 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 12 · Phase 3 4 · Phase 4 3
First in 1998; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is below the median of 61 across 56 interventional studies indexed under Mucopolysaccharidosis IV.
Median enrollment 88 across the 30 interventional studies, 131 across the 25 observational. Of the 36 that completed or were terminated, 10 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 56 have an industry lead sponsor. The 10 most frequent:
This study is registered under QED Therapeutics, a BridgeBio company, one of the names counted as BridgeBio. Under that name alone:
QED Therapeutics, a BridgeBio company is the lead sponsor of 8 studies on the registry; 5 are open to participants now.
BridgeBio has 8 studies filed under Mucopolysaccharidosis IV — fewer than ten, so there is no comparison to draw.
5 of the studies in Mucopolysaccharidosis IV with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06873035Phase 3QED Therapeutics, a BridgeBio companyAn Interventional Study of Infigratinib in Children With Hypochondroplasia | 2027-01 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT04152551Hospital for Special Surgery, New YorkEffects of Bisphosphonates on OI-Related Hearing Loss | 2027-01 |
| NCT05284006Nemours Children's ClinicNon-invasive Functional Assessment and Pathogenesis of Morquio A | 2027-04-30 |
| NCT05031507Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Study of Skeletal Disorders | 2027-07-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 56 studies in Mucopolysaccharidosis IV with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
ACCEL2/3 is a Phase 2/3 study. The purpose of the Phase 2 portion of the study (ACCEL2/3) is to evaluate the efficacy and safety of infigratinib in children with hypochondroplasia (HCH) receiving infigratinib at one of two doses, who have completed at least 26 weeks of participation in QED-sponsored ACCEL (QBGJ398-004).
ACCEL 2/3 is a Phase 2/3 study that comprises of 2 portions. The Phase 2 portion is an open-label, portion in children with HCH aged 5 to 11 years old followed by a Phase 3 portion which is double-blind, placebo-controlled in children with HCH aged >3 years old to \<18 years old.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral infigratinib 0.128 mg/kg/day
Drug: infigratinib 0.128 mg/kg/day
Oral infigratinib 0.25 mg/kg/day
Drug: infigratinib 0.25 mg/kg/day
Drug page: Infigratinib
Oral infigratinib 0.128 mg/kg/day
Drug page: Infigratinib
Oral infigratinib 0.25 mg/kg/day
Change from baseline (BL) in Annualized Height Velocity (AHV; cm/year)
Time frame: 26 weeks
Incidence, severity, and seriousness of adverse events (AEs) that require dose reduction or discontinuation
Time frame: at least 26 weeks
Change from BL in height Z-score (in relation to both HCH and average height tables)
Time frame: 52 weeks
Change from BL in upper to lower body segment ratio (cm)
Time frame: 52 weeks
Changes in cognitive function (as assessed by age appropriate computerized tests)
Time frame: 52 weeks
Pharmacokinetic profile of infigratinib by assessment of maximum concentration (Cmax)
Time frame: 52 weeks
Pharmacokinetic profile of infigratinib by assessment of time-to-maximum concentration (Tmax)
Time frame: 52 weeks
Change from BL in collagen X marker (CXM) levels
Time frame: 52 weeks
Change from BL in comorbidities associated with HCH
Time frame: 52 weeks
Change from BL in Health-related Quality of Life (HRQoL) (as assessed by Pediatric Quality of Life Inventory [PedsQL tool])
Time frame: 52 weeks
Evaluate treatment benefit as assessed by qualitative interviews
Time frame: 52 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Jan 2027, 21 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Infigratinib
QED Therapeutics, a BridgeBio company →